findmyKOL
Clinical trialNCT02327078CompletedPhase 1/PHASE2Interventional

A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)

SponsorIncyte CorporationEnrollment307B-cell MalignanciesColorectal Cancer (CRC)GlioblastomaHead and Neck CancerLung CancerLymphoma+2 more conditions
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

24 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United Kingdom
  • the Christie Nhs Foundation Trust

    Manchester, United Kingdom

  • Oxford University Hospitals Nhs Trust

    Oxford, United Kingdom

United States
  • Uab Comprehensive Cancer Center

    Birmingham, Alabama, United States

  • the Angeles Clinic and Research Institute

    Los Angeles, California, United States

  • Usc Norris Cancer Center

    Los Angeles, California, United States

  • Ucsf - University of California San Francisco

    San Francisco, California, United States

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado, United States

  • the University of Kansas Clinical Research Center

    Fairway, Kansas, United States

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland, United States

  • Dana Farber Cancer Institute

    Boston, Massachusetts, United States

  • Lahey Hospital & Medical Center

    Burlington, Massachusetts, United States

  • Columbia University, Herbert Irving Comprehensive Cancer Center

    New York, New York, United States

  • Nyu Cancer Center

    New York, New York, United States

  • Duke University Medical Center

    Durham, North Carolina, United States

  • Wake Forest Medical Center Boulevard

    Winston-Salem, North Carolina, United States

  • Sanford Research

    Fargo, North Dakota, United States

  • University of Pittsburgh School of Medicine

    Pittsburgh, Pennsylvania, United States

  • Sanford Research

    North Sioux City, South Dakota, United States

  • Vanderbilt University Medical Center

    Nashville, Tennessee, United States

  • Texas Oncology Research

    Austin, Texas, United States

  • Md Anderson Cancer Center

    Houston, Texas, United States

  • Huntsman Cancer Institute

    Salt Lake City, Utah, United States

  • Utah Cancer Specialists

    Salt Lake City, Utah, United States

  • Medical College of Wisconsin

    Milwaukee, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
26 Nov 2014
Primary completion
16 Jun 2020
Completion
16 Jun 2020
Last update posted
14 Aug 2025
Registered enrollment
307
Registry id
NCT02327078

Cross-registrations

EU-CTR / CTIS (EudraCT)2016-002423-29

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.